Carboplatin hypersensitivity has rarely been reported in patients receiving repeated cycles of therapy, but has not been reported in transplant settings. We report a case of carboplatin hypersensitivity during conditioning for autologous PBSC transplantation. The patient suddenly developed chest tightness, hemoptysis, hypoxia and hypotension, resulting in a transient myocardial ischemia. The pathophysiologic mechanism for the event seemed to be non-immune-mediated direct histamine release given the lack of prior exposure to platinum. Contrary to advice not to continue further treatment with carboplatin by some authors, we successfully desensitized the patient and subsequently gave more carboplatin as a part of conditioning. Awareness of carboplatin as one of the causes of hypersensitivity may help avoid further problems either by substitution or desensitization, along with premedications. Keywords: carboplatin; hypersensitivity; conditioning; PBSC transplantation; desensitization Carboplatin, a second-generation, platinum-containing chemotherapeutic agent, is increasingly used in transplant conditioning regimens for a variety of solid tumors. Although type I hypersensitivity has been reported in 1% to 20% of patients who receive cisplatin, there are few reports of similar reactions in patients receiving repeated cycles of carboplatin therapy.
Carboplatin, a second-generation, platinum-containing chemotherapeutic agent, is increasingly used in transplant conditioning regimens for a variety of solid tumors. Although type I hypersensitivity has been reported in 1% to 20% of patients who receive cisplatin, there are few reports of similar reactions in patients receiving repeated cycles of carboplatin therapy. 1, 2 To our knowledge, there have been no reported cases of life-threatening carboplatin hypersensitivity in the transplant setting.
We report a case of carboplatin hypersensitivity who presented with hemoptysis and hypoxia resulting in transient myocardial ischemia during conditioning for autologous PBSC transplantation. Most of the patients reported who have had allergic reactions to carboplatin were unable to tolerate further treatment with it despite heavy premedication with steroids and antihistaminics. 1, 3 In our case, however, carboplatin was re-introduced successfully as a conditioning regimen after a course of desensitization.
Case report
An 8-year-old girl was admitted for autologous PBSC transplantation. One year earlier she had developed fever and jaundice, and was diagnosed to have a sarcoma botryoides arising in the bile duct. The tumor was stage III and only a partial resection was possible at that time. Chemotherapy consisting of vincristine, actinomycin-D and ifosfamide (VAI) along with radiotherapy had effected a good response on the second-look operation. A total of six leukaphereses were performed by CS3000+ after two mobilization cycles employing VAI plus G-CSF. The planned conditioning regimen was: carboplatin 800 mg/m 2 once daily i.v. on days Ϫ6 and Ϫ5, etoposide 200 mg/m 2 twice daily i.v. on days Ϫ6 to Ϫ4 (total six doses), and melphalan 180 mg/m 2 i.v. on day Ϫ2. The first morning dose of etoposide was administered uneventfully. Carboplatin was dissolved in 500 ml of D 5 . saline solution. Five minutes after starting the infusion when a total of about 10 mg of carboplatin had been administered, she suddenly developed tachypnea, chest tightness, cyanosis, vomiting, cough, hemoptysis and hypotension. The infusion was immediately interrupted and she was resuscitated with oxygenation, fluid therapy, steroids and antihistaminics. Dopamine and aminophylline were added.
The chest X-ray, showing bilateral, wide-spread pulmonary infiltrates along with hemoptysis, suggested diffuse pulmonary hemorrhage. No fever was noted. Extensive cultures failed to identify any septic organism. The only medications she had taken were oral fluconazole and ofloxacine as prophylaxis. An electrocardiogram revealed tachycardia with T wave inversions in leads I, II and throughout chest leads. On the following day, repeat echocardiogram showed reduced cardiac contractility (ejection fraction, 0.51; fractional shortening, 26.3%) with wall dyskinesia, different from the normal findings of 4 days earlier at pretransplant work-up.
99m -Tc tetrofosmin scan of myocardium showed a reversible perfusion defect suggesting inferoseptal wall ischemia. She was further treated with l-carnitine.
Serial chest X-ray showed rapid improvement with near normal appearance in 3 days. Five days after the episodes, follow-up echocardiography disclosed normalization of cardiac contractility, but EKG changes persisted over several weeks.
As both carboplatin and VP-16 are essential in the highdose strategy, we decided to re-challenge with the same drugs after desensitization. Six weeks after the incident desensitization with carboplatin was carried out according to VanArsdel's method. 4 Briefly, three doses of prednisolone 25 mg were given orally 13, 7 and 1 h before the desensitization in addition to 25 mg of hydroxyzine and 300 mg of cimetidine given 1 h prior to desensitization. Carboplatin was diluted in saline and the doses were prepared as 0.002, 0.02, 0.2 and 2 mg. Each dose of carboplatin was given intravenously four times every 15 min. Then, the doses were increased when the previous dose was tolerated uneventfully. The whole process was completed without any problems.
One week later, she was readmitted to undergo PBSC transplantation. Skin test to carboplatin was negative. The same conditioning regimen was used. Carboplatin was administered successfully after premedication with an oral dose of diphenhydramine 50 mg and three doses of prednisolone 25 mg 13, 7 and 1 h beforehand. The PBSC infused consisted of 5. + cells. Her post-transplant course was complicated by severe mucositis, paralytic ileus, gram-negative sepsis and Candida pelliculosa infection. She died of complications despite aggressive antibiotic therapy while still neutropenic on day +10. Bone marrow aspiration done before her death showed early evidence of trilineage engraftment. Permission for autopsy was not granted.
Discussion
Carboplatin is a platinum analogue developed to minimize the dose-limiting audio-and nephrotoxicities of cisplatin. Shown to be effective against solid tumors such as neuroblastoma, brain tumors and germ cell tumors in children, as well as ovarian tumors and small cell lung cancer in adults, carboplatin is increasingly used as a component of high-dose conditioning regimens with stem cell rescue, as in cyclophosphamide, thiotepa and carboplatin combination, or ifosfamide, carboplatin and etoposide combination for various solid tumors.
Although hypersensitivity to cisplatin has been reported to occur in 1% to 20% of patients, carboplatin has rarely been implicated as a cause of hypersensitivity reactions. [1] [2] [3] The clinical features of allergic reactions to carboplatin have resembled the symptoms of a histamine-induced type I hypersensitivity reaction, usually developing soon after the onset of an infusion. Symptoms have included respiratory (wheezing, dyspnea), gastrointestinal (abdominal cramps, diarrhea), and dermatologic symptoms (pruritus, urticaria, facial erythema, and swelling). 5 Severity of reactions ranged from transient and mild reactions resembling common side-effects of anti-cancer chemotherapy or nearfatal anaphylaxis. 1, 5 However, massive pulmonary infiltrations with hemoptysis and hypoxia resulting in transient myocardial ischemia as seen in this case have not been reported to date. Most cases of hypersensitivity to carboplatin have occurred in patients receiving repeated cycles of carboplatin, denoting the slow development of hypersensitivity in general.
1,2 Chang et al 5 reported the evolution of hypersensitivity reactions after 12 weekly infusions of carboplatin on average. No hypersensitivity reactions, however, were described in several studies which employed high-dose carboplatin with autologous bone marrow support. 5 This contrast might be a result of the single, large exposure to the drug, rather than the repeated infusions used in the other studies.
The pathophysiologic mechanisms of hypersensitivity to platinum derivatives, although not entirely elucidated, appears to be mediated by type I hypersensitivity reactions as well as by non-immune-mediated direct release of histamine from mast cells and basophils unrelated to IgE production. 1, [6] [7] [8] The mechanism of hypersensitivity in this patient seemed to be the latter as she had no previous sensitization to either carboplatin or cisplatin.
Other possibilities that might mimic such an event were: (1) infection with septic shock; (2) late anaphylactoid reaction to etoposide; and (3) hypersensitivity to mannitol or other compounds included in commercial formulations of carboplatin. 9 Failure to identify any organisms and the lack of any apparent inflammatory signs, such as fevers, and prompt recovery without changes of antibiotics, make the infectious etiology less likely. Moreover, etoposide and mannitol were given again (without desensitization) and no anaphylaxis developed. This fact suggested that these two drugs were not involved in the event. However, the immediate occurrence after the infusion and successful prevention of symptoms after desensitization strongly suggested carboplatin as the cause of the event.
In view of its well-documented effectiveness against the tumor, carboplatin was tried again after premedication with corticosteroids and antihistaminics. Although successful in some, 10 readministration has generally been considered dangerous and is not recommended as it might provoke severe reactions despite intensive premedications. 1, 3, 5 In cases of hypersensitivity to carboplatin, switching to cisplatin-containing cytostatic regimens was tolerated well in most, but not in all patients. 1, 7 Windom et al 11 reported a case of successful retreatment with carboplatin after desensitization in a patient with ovarian adenocarcinoma. In our case, as carboplatin was thought to be essential in a high-dose strategy, we successfully readministered it after desensitization.
In conclusion, we should be aware of carboplatin as one of the possible causes of hypersensitivity in order to avoid life-threatening accidents with further therapy, either by substituting another drug or by desensitization along with heavy premedication. 
